Safety and immunogenicity of the quadrivalent HPV vaccine in female Systemic Lupus Erythematosus patients aged 12 to 26 years

BACKGROUND: Women with SLE have higher rates of persistent human papilloma virus (HPV) infections and precancerous lesions than healthy women. HPV vaccine is safe and effective in healthy females aged 9–26 years. There are limited data on the safety and immunogenicity of HPV vaccine in females with...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Soybilgic, Arzu, Onel, Karen B, Utset, Tammy, Alexander, Kenneth, Wagner-Weiner, Linda
Format: Artigo
Jezik:Inglês
Izdano: BioMed Central 2013
Teme:
Research
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3751269/
https://ncbi.nlm.nih.gov/pubmed/23924237
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1546-0096-11-29
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items